<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561807</url>
  </required_header>
  <id_info>
    <org_study_id>VX11-787-101</org_study_id>
    <nct_id>NCT01561807</nct_id>
  </id_info>
  <brief_title>A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Effects of VX-787 Administered to Adult Volunteers Experimentally Inoculated With Live Influenza Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antiviral activity and safety of VX-787 given
      to healthy adult volunteers that have been inoculated with the influenza virus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is viral AUC as calculated in cell culture of nasal swabs (quantitation of nasal swabs for viral infectivity by cell culture), from initiation of VX-787 treatment</measure>
    <time_frame>up to 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability based on assessment of adverse events, clinical laboratory assessments, 12-lead electrocardiograms (ECGs), and vital signs.</measure>
    <time_frame>up to 33 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total tissue count and total mucus weight after viral inoculation</measure>
    <time_frame>up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence analysis of the relevant target region of influenza</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of VX-787</measure>
    <time_frame>8 days</time_frame>
    <description>As measured by AUC, Cmax, tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite symptom score AUC</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral AUC calculated by RT-PCR of nasal swabs, from initiation of VX-787 treatment</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of viral shedding by cell culture and/or RT-PCR</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak viral shedding titer by cell culture and/or RT-PCR</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution from peak viral shedding by cell culture and/or RT-PCR</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak of composite sympton score, duration, and time to resolution of composite score from peak</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak severity of symptoms after viral inoculation</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of influenza-like illness after viral inoculation</measure>
    <time_frame>up to 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Influenza Virus</condition>
  <arm_group>
    <arm_group_label>787 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-787 low dose capsule, taken orally for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>787 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-787 high dose capsule, taken orally for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo low dose capsule, taken orally for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo high dose capsule, taken orally for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-787</intervention_name>
    <arm_group_label>787 low dose</arm_group_label>
    <arm_group_label>787 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo low dose</arm_group_label>
    <arm_group_label>Placebo high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Negative human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C(HCV)
             antibody screen

          -  Have not been vaccinated for influenza virus since 2006 or had a known influenza-like
             illness in the current season (as determined in the medical history), defined as in
             the last 12 months before Screening

        Exclusion Criteria:

          -  Subjects who are pregnant or nursing, or who are male and have a female partner who is
             pregnant, nursing, or is planning to become pregnant during the study period (from at
             least 14 days before the first dose until 90 days of the last dose of study drug)

          -  Presence of any significant acute or chronic, uncontrolled medical or psychiatric
             illness

          -  Abnormal pulmonary function as evidenced by clinically significant abnormalities in
             spirometry

          -  Health care workers (including doctors, nurses, medical students and allied healthcare
             professionals) anticipated to have patient contact within two weeks of viral
             inoculation

          -  Intending to travel(to countries for which vaccinations are recommended or where high
             risk of infections exists)

          -  Subjects with a history of asthma, COPD, pulmonary hypertension, reactive airway
             disease, or any chronic lung condition of any etiology; any history during adulthood
             of asthma of any etiology, COPD, or any use of a bronchodilator or other asthma
             medication during adulthood

          -  Regular daily smokers

          -  History or evidence of autoimmune disease or known impaired immune responsiveness

          -  History of heart failure or any other severe cardiac abnormality including clinically
             significant arrhythmia

          -  Receipt of any investigational drug within 3 months, or prior participation in a
             clinical trial of any influenza vaccine, medication, or experimental respiratory viral
             challenge delivered directly to the respiratory tract within 1 year before viral
             inoculation

          -  Previous exposure to study drug or similar substance(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Trevejo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <disposition_first_submitted>January 8, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 8, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 6, 2014</disposition_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

